Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 7
2004 8
2005 4
2006 2
2007 3
2008 5
2009 5
2010 6
2011 14
2012 16
2013 10
2014 6
2015 12
2016 8
2017 7
2018 15
2019 14
2020 16
2021 16
Text availability
Article attribute
Article type
Publication date

Search Results

156 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Mittendorf EA, et al. Among authors: saji s. Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20. Lancet. 2020. PMID: 32966830 Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: saji s. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y. Tamura K, et al. Among authors: saji s. J Clin Oncol. 2020 Feb 20;38(6):558-566. doi: 10.1200/JCO.19.01412. Epub 2019 Dec 10. J Clin Oncol. 2020. PMID: 31821071 Free PMC article. Clinical Trial.
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Yamashita T, et al. Among authors: saji s. Trials. 2020 May 7;21(1):391. doi: 10.1186/s13063-020-04341-y. Trials. 2020. PMID: 32381018 Free PMC article. Clinical Trial.
Genomic tumor evolution of breast cancer.
Sato F, Saji S, Toi M. Sato F, et al. Among authors: saji s. Breast Cancer. 2016 Jan;23(1):4-11. doi: 10.1007/s12282-015-0617-8. Epub 2015 May 22. Breast Cancer. 2016. PMID: 25998191 Review.
Early breast cancer.
Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Suzuki T, et al. Among authors: saji s. Int J Clin Oncol. 2006 Apr;11(2):108-19. doi: 10.1007/s10147-006-0564-7. Int J Clin Oncol. 2006. PMID: 16622745 Review.
Brain metastases in breast cancer.
Niikura N, Saji S, Tokuda Y, Iwata H. Niikura N, et al. Among authors: saji s. Jpn J Clin Oncol. 2014 Dec;44(12):1133-40. doi: 10.1093/jjco/hyu156. Epub 2014 Oct 15. Jpn J Clin Oncol. 2014. PMID: 25320339 Review.
Trastuzumab: updates and future issues.
Toi M, Horiguchi K, Bando H, Saji S, Chow LW. Toi M, et al. Among authors: saji s. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:94-9. doi: 10.1007/s00280-005-0110-8. Cancer Chemother Pharmacol. 2005. PMID: 16273357 Review.
156 results